Fosbretabulin
- Generic Name
- Fosbretabulin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21O8P
- CAS Number
- 222030-63-9
- Unique Ingredient Identifier
- I5590ES2QZ
- Background
Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
- Conditions
- Neuroendocrine TumorsEverolimus
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Lowell Anthony, MD
- Target Recruit Count
- 17
- Registration Number
- NCT03014297
- Locations
- ๐บ๐ธ
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
- Conditions
- Platinum Resistant Ovarian Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT02641639
- Locations
- ๐บ๐ธ
Sansum Clinic, Santa Barbara, California, United States
๐บ๐ธMitchell Cancer Institute - USA Health System, Mobile, Alabama, United States
๐บ๐ธUniversity of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT02279602
- Locations
- ๐บ๐ธ
Froedtert Hospital, Medicial College of Wisconsin, Milwaukee, Wisconsin, United States
๐บ๐ธMontefiore, Bronx, New York, United States
๐บ๐ธMarkey Cancer Center, Clinical Research Office, Lexington, Kentucky, United States
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT02132468
- Locations
- ๐บ๐ธ
Duke University Medical Center, Durham, North Carolina, United States
๐บ๐ธStanford University School of Medicine, Stanford, California, United States
๐บ๐ธMarkey Cancer Center, Clinical Research Office, Lexington, Kentucky, United States
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
- Conditions
- Neoplasms, OvarianOvarian NeoplasmsOvarian Cancer
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 21
- Registration Number
- NCT02055690
- Locations
- ๐ฌ๐ง
University Collage London Hospitals NHS Foundation Trust, London, United Kingdom
๐ฌ๐งThe Christie NHS Foundation Trust, Manchester, United Kingdom
๐ฌ๐งFreeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Newcastle Upon Tyne, United Kingdom
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
- Conditions
- Anaplastic Thyroid Cancer
- Interventions
- Drug: Placebo + paclitaxel + carboplatin
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Mateon Therapeutics
- Registration Number
- NCT01701349
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
- Conditions
- Combretastatin A4 PhosphateAge-related Macular DegenerationCNVChoroidal NeovascularizationAMD
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 8
- Registration Number
- NCT01570790
- Locations
- ๐บ๐ธ
Wilmer Eye Institute, Baltimore, Maryland, United States
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Conditions
- Choroidal NeovascularizationMyopia, Degenerative
- Interventions
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT01423149
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- Conditions
- Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT01305213
- Locations
- ๐บ๐ธ
West Michigan Cancer Center, Kalamazoo, Michigan, United States
๐บ๐ธMaine Medical Center-Bramhall Campus, Portland, Maine, United States
๐บ๐ธSinai Hospital of Baltimore, Baltimore, Maryland, United States
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- Drug: Saline
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT01023295
- Locations
- ๐จ๐ณ
OXiGENE Investigational Site, Changhua, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.